The United States Court of Appeals for the Third Circuit has sided with Johnson & Johnson (J&J) and its Janssen division, requiring a dispute between the Remicade maker and Rochester Drug Cooperative to be sent to arbitration.
The United States Court of Appeals for the Third Circuit has sided with Johnson & Johnson (J&J) and its Janssen division, requiring a dispute between the Remicade maker and Rochester Drug Cooperative (RDC) to be sent to arbitration.
RDC is a direct purchaser and wholesaler of Remicade, J&J’s brand-name infliximab. RDC had alleged that J&J engaged in anticompetitive practices related to its “Biosimilars Readiness Plan,” which RDC said included exclusionary contracting with insurers, product bundling with insurers, and similar contracting and bundling with healthcare providers.
In its complaint, filed in 2018, RDC noted that, despite competition from biosimilars, J&J’s brand-name infliximab maintained and even increased its prices. “J&J did not achieve this unusual result by competition on the merits,” said the complaint, “but instead through a multifaceted scheme to block biosimilar competition to Remicade through a web of exclusive dealing contracts.”
RDC brought claims against J&J under the Sherman Act based on alleged anticompetitive conduct, and J&J later moved to compel arbitration of the dispute, saying that the claims arose out of a 2015 distribution agreement between J&J and RDC and the agreement contains a clause related to resolution of disputes. According to J&J, the courts must rigorously enforce the terms of arbitration agreements, and RDC is obligated to arbitrate antitrust claims against the drug maker because Remicade is one product specifically referenced in the 2015 agreement between the 2 parties.
A district court, in October 2018, denied J&J’s motion to compel arbitration, saying that RDC’s claims could not be resolved based on the agreement. On appeal, however, the court agreed with J&J, and reversed the district court’s judgment in the case, saying that RDC’s claims relate to the 2015 agreement and therefore must be subject to arbitration.
This case is just one of multiple cases related to J&J’s strategy to defend its market share for infliximab. In 2017, Pfizer filed an antitrust suit against J&J, alleging that the drug maker’s tactics had effectively denied patients access to biosimilar therapies (including Pfizer’s Inflectra) and undermined price competition in the biologics marketplace.
Additionally, in July of this year, a regulatory filing by Janssen revealed that the Federal Trade Commission had issued civil subpoenas to J&J as part of an antitrust investigation into the drug company’s contracting practices.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.